Table 1.
Number of patients | N = 16 | |
Age | ||
Median | 59 | |
Range | 36–73 | |
Male:female | 14:2 | |
ECOG performance status | ||
0 | 6 | 37% |
1 | 8 | 50% |
2 | 2 | 13% |
Disease status | ||
Primary metastatic | 12 | 75% |
Locally-advanced | 4 | 25% |
Prior chemotherapy | ||
Uracil-tegafur | 4 | 25% |
5-FU bolus + folinic acid | 1 | 6% |
5-FU + cisplatin | 4 | 25% |
Epirubicin + cisplatin + capecitabine | 5 | 31% |
Epirubicin + doxorubicin + cisplatin | 2 | 13% |